Safety of Luspatercept in Korean Patients With Blood Disorders
Studies real-world safety of luspatercept in Korean adults with myelodysplastic syndrome or beta thalassemia.
Plain-language title generated from the registry record
Registry title: A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
Key facts
- Where
- Seoul, South KoreaSee the 2 sites
Where in South Korea
- Novotech Laboratory Korea Co., Ltd.Seoul, South KoreaTaking people
- SeoulSeoul, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06073860
- Record updated
- 6 November 2024
- Original description
The purpose of this observational study is to assess the real-world safety of luspatercept in Korean participants with myelodysplastic syndrome (MDS) or beta thalassemia. Investigators will enroll participants who will begin treatment with at least 1 dose of luspatercept.Read full original descriptionShow less
Reblozyl® (Luspatercept) Post-Marketing Surveillance in Korean Patients With Myelodysplastic Syndrome or Beta Thalassemia
The purpose of this observational study is to assess the real-world safety of luspatercept in Korean participants with myelodysplastic syndrome (MDS) or beta thalassemia. Investigators will enroll participants who will begin treatment with at least 1 dose of luspatercept.
Inclusion: Adult participants 19 years of age or older; Participants who will be treated with luspatercept according to the approved label in the Republic of Korea; Participants who sign the informed consent form.
Exclusion: Participants for whom luspatercept is contraindicated as clarified in the Korean prescribing information approved by the Ministry of Food and Drug Safety; Participants who are prescribed luspatercept for therapeutic indications not approved in the Republic of Korea.